Four point-of-care tests for UTIs ‘show promise’, says NICE in early guidance NICE said it needs more data on the accuracy of the tests in detecting and identifying bacteria before it can recommend them for use in the NHS.…
Weight loss drug semaglutide will ‘soon’ be available to eligible patients, says NICE Trial results showed that participants taking semaglutide lost an average of 12% more of their body weight compared with placebo.…
Apps for treatment of anxiety and depression in adults provisionally approved by NICE The eight digital therapies include treatments for body dysmorphic disorder and post-traumatic stress disorder.…
NICE alters guidance on COVID-19 treatments as manufacturer withdraws marketing authorisation application The National Institute of Health and Care Excellence said the guidance has changed because Eli Lily is no longer seeking a marketing authorisation for baricitinib (Olumiant).…
UTIs can be diagnosed without a dipstick test, says NICE The National Institute for Health and Care Excellence has said women aged under 65 years can be diagnosed with urinary tract infection if they have two or more key urinary symptoms and no other excluding causes or warning signs.…
Alternative to injections for people with severe migraines approved for use on NHS Eptinezumab, a calcitonin gene-related peptide inhibitor, will be available on the NHS for people with episodic and chronic migraines who meet certain conditions.…
Should all adults be considered for statin therapy? A closer look at the arguments for and against the latest changes to National Institute for Health and Care Excellence guidelines for statin therapy.…
Appetite suppressant approved by NICE for patients with obesity The National Institute for Health and Care Excellence recommends that semaglutide should be considered in adults with at least one weight-related condition and a body mass index of at least 35.…
Updated NICE guidance for type 2 diabetes: what do you need to know? In this episode of the PJ Pod, we explore the main changes and implications for practice brought about by the National Institute for Health and Care Excellence update to the ‘Type 2 diabetes in adults: management’ guideline.…
NICE to approve icosapent ethyl for some high-risk cardiovascular patients The National Institute for Health and Care Excellence says 425,000 people with established cardiovascular disease could benefit from treatment with icosapent ethyl.…
